Table 49.

Incremental cost-effectiveness ratios for situations where adalimumab is readily available compared to when it is unavailable.

Time Horizon	Utility score of response to adalimumab measured by time-trade-off (u = 0.79)	Utility score of response to adalimumab measured by visual rating scale (u = 0.82)
5-year	$45,000 ($25,000–$65,000)	$40,000 ($22,000–$58,000)
10-year	$59,000 ($37,000–$81,000)	$53,000 ($33,000–$72,000)
15-year	$68,000 ($45,000–$91,000)	$60,000 ($40,000–$81,000)